Effect of consumption of Cacao 72% dark chocolate for 4 weeks on blood pressure, fasting serum lipid profile, cognitive function, and markers of oxidative stress and inflammation in Japanese 45-69 subjects: single group pre-post trial

Effect of consumption of Cacao 72% dark chocolate for 4 weeks on blood pressure, fasting serum lipid profile, cognitive function, and markers of oxidative stress and inflammation in Japanese 45-69 subjects: single group pre-post trial - Effect of consumption of Cacao 72% dark chocolate for 4 weeks on blood pressure, fasting serum lipid profile, cognitive function, and markers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022168

Enrollment

400

Registered

2016-05-02

Start date

2014-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

72% Cacao Dark chocolate 25 g/day for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Persons who give written informed consent, and have full ethical and regulatory approval 2. Persons who are currently health adults and 45-69 years

Exclusion criteria

Exclusion criteria: 1. Persons who are currently medication for chronic disease 2. Persons who take pharmaceuticals, dairy supplement, health-promoting diet and health food for the purpose of health maintenance related to the test food of this trial within the last three months 3. Persons who were enrolled into other clinical trials within the last one month before agreeing to participate in this trial 4. Persons who are allergic to cacao products to the test food of this trial, milk protein, and soybean 5. Persons who took the cacao products daily in large quantity 6. Persons who are pregnant, or planning to get pregnant during the trial period 7. Persons who are lactating 8. Persons who are judged unsuitable for participating in this trial by physician

Design outcomes

Primary

Measure	Time frame
Blood pressure (systolic blood pressure, diastolic blood pressure) and insulin resistance index (HOMA-IR, QUICKI) after 4 weeks of intervention	—

Secondary

Measure	Time frame
Glucose, Insulin, Blood Lipid (Total cholesterol, HDL-Cholesterol, LDL-cholesterol, Triglyceride), Brain Derived Neurotrophic Factor Hs-CRP, 8-OHdG, SF-36	—

Countries

Japan

Contacts

Public ContactHirohito Ishikawa

Healthcare Systems Co., Ltd. Research and Development

ishikawa@hc-sys.jp03-6809-2722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026